Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies.

• Main Authors: Christian Burri (Author), Patrick D Yeramian (Author), James L Allen (Author), Ada Merolle (Author), Kazadi Kyanza Serge (Author), Alain Mpanya (Author), Pascal Lutumba (Author), Victor Kande Betu Ku Mesu (Author), Constantin Miaka Mia Bilenge (Author), Jean-Pierre Fina Lubaki (Author), Alfred Mpoo Mpoto (Author), Mark Thompson (Author), Blaise Fungula Munungu (Author), Francisco Manuel (Author), Théophilo Josenando (Author), Sonja C Bernhard (Author), Carol A Olson (Author), Johannes Blum (Author), Richard R Tidwell (Author), Gabriele Pohlig (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2016-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BACKGROUND:Sleeping sickness (human African trypanosomiasis [HAT]) is caused by protozoan parasites and characterized by a chronic progressive course, which may last up to several years before death. We conducted two Phase 2 studies to determine the efficacy and safety of oral pafuramidine in Africa...